Abstracts

Total neoadjuvant therapy (TNT) in early-onset (EO) vs average-onset (AO) locally advanced rectal cancer (LARC): Patient characteristics and tolerance

Background TNT increases the rate of clinical complete response (cCR), which may allow more patients to proceed with watch-and-wait (WW) surveillance. Patients with EO (< 50 years of ...

07/01/2022

Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial

Background We previously described a prognostic role for the glycoprotein STC1 in patients with metastatic CRC (mCRC) receiving first-line chemotherapy and in a small number of patients ...

07/01/2022

A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer

Background Previous studies showed that intravenously high dose vitamin C probably have anti-cancer effect. Preclinical study found that high dose vitamin C selectively killed human colo...

07/01/2022

Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies

Background Trifluridine/tipiracil (FTD/TPI) is approved for use in patients with metastatic colorectal cancer (mCRC) who have progressed on, or who cannot tolerate, standard therapies. P...

07/01/2022

Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer

Background In primary analysis from the TRUSTY study, trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) failed to show non-inferiority in terms of overall survival (OS) to irinotec...

07/01/2022

Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab – secondary endpoint

Background FIRE-4 (AIO KRK-0114) is performed in RAS-wild-type (wt) mCRC patients. This randomized study tests the efficacy of early switch maintenance during 1st-line therapy (part 1) a...

07/01/2022

Impact of sequencing of different treatment modalities on survival outcomes among patients with non-metastatic hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) is the most common type of liver malignancy and the third leading cause of cancer-related death in the world. Liver transplant is a cornerstone ...

F. Baidoun ;

O. Abdel-Rahman ;

06/30/2022

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study

Background The phase III IMbrave150 trial led to the approval of immunotherapy with atezolizumab plus bevacizumab as a new first-line standard of care for patients with advanced hepatoce...

06/30/2022

Response evaluation after neoadjuvant chemotherapy for resectable gastric cancer: Downsizing vs downstaging

Background Response evaluation following neoadjuvant chemotherapy (NAC) in resectable gastric cancer is debated. The aims of the present study were to investigate the value of strict rad...

06/30/2022

The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients: Results from the UK MRC OE02 trial

Background Patients with resectable oesophageal cancer (OeC) have a 25-47% 5-year overall survival (OS). The strongest prognostic factor is pathological lymph node (LN) status. Regional ...

06/30/2022